104 related articles for article (PubMed ID: 19892410)
1. Lack of association between antipsychotic-induced extrapyramidal symptoms and polymorphisms in dopamine metabolism and transport genes.
Gassó P; Mas S; Crescenti A; Alvarez S; Parramon G; Garcia-Rizo C; Parellada E; Bernardo M; Lafuente A
Psychiatry Res; 2010 Jan; 175(1-2):173-5. PubMed ID: 19892410
[TBL] [Abstract][Full Text] [Related]
2. Lack of association between schizophrenia and polymorphisms in dopamine metabolism and transport genes.
Alvarez S; Mas S; Gassó P; Bernardo M; Parellada E; Lafuente A
Fundam Clin Pharmacol; 2010 Dec; 24(6):741-7. PubMed ID: 20041956
[TBL] [Abstract][Full Text] [Related]
3. The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol.
Zivković M; Mihaljević-Peles A; Bozina N; Sagud M; Nikolac-Perkovic M; Vuksan-Cusa B; Muck-Seler D
J Clin Psychopharmacol; 2013 Oct; 33(5):593-9. PubMed ID: 23963056
[TBL] [Abstract][Full Text] [Related]
4. Associations between polymorphisms in dopamine neurotransmitter pathway genes and pain response in healthy humans.
Treister R; Pud D; Ebstein RP; Laiba E; Gershon E; Haddad M; Eisenberg E
Pain; 2009 Dec; 147(1-3):187-93. PubMed ID: 19796878
[TBL] [Abstract][Full Text] [Related]
5. Dopamine transporter (DAT) genotype (VNTR) and phenotype in extrapyramidal symptoms induced by antipsychotics.
Lafuente A; Bernardo M; Mas S; Crescenti A; Aparici M; Gassó P; Catalan R; Mateos JJ; Lomeña F; Parellada E
Schizophr Res; 2007 Feb; 90(1-3):115-22. PubMed ID: 17150335
[TBL] [Abstract][Full Text] [Related]
6. Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms.
Güzey C; Scordo MG; Spina E; Landsem VM; Spigset O
Eur J Clin Pharmacol; 2007 Mar; 63(3):233-41. PubMed ID: 17225991
[TBL] [Abstract][Full Text] [Related]
7. Cyp2d6*3, *4, *5 and *6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapy.
Crescenti A; Mas S; Gassó P; Parellada E; Bernardo M; Lafuente A
Clin Exp Pharmacol Physiol; 2008 Jul; 35(7):807-11. PubMed ID: 18346175
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics of adverse events in schizophrenia treatment: comparison study of ziprasidone, olanzapine and perazine.
Tybura P; Trześniowska-Drukała B; Bienkowski P; Beszlej A; Frydecka D; Mierzejewski P; Samochowiec A; Grzywacz A; Samochowiec J
Psychiatry Res; 2014 Oct; 219(2):261-7. PubMed ID: 24930580
[TBL] [Abstract][Full Text] [Related]
9. Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia.
Kaiser R; Tremblay PB; Klufmöller F; Roots I; Brockmöller J
Mol Psychiatry; 2002; 7(7):695-705. PubMed ID: 12192613
[TBL] [Abstract][Full Text] [Related]
10. A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms.
Gassó P; Mas S; Bernardo M; Alvarez S; Parellada E; Lafuente A
Pharmacogenomics J; 2009 Dec; 9(6):404-10. PubMed ID: 19506579
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms of dopamine degradation enzyme (COMT and MAO) genes and tardive dyskinesia in patients with schizophrenia.
Matsumoto C; Shinkai T; Hori H; Ohmori O; Nakamura J
Psychiatry Res; 2004 Jun; 127(1-2):1-7. PubMed ID: 15261699
[TBL] [Abstract][Full Text] [Related]
12. Case-control study of dopamine transporter-1, monoamine oxidase-B, and catechol-O-methyl transferase polymorphisms in Parkinson's disease.
Goudreau JL; Maraganore DM; Farrer MJ; Lesnick TG; Singleton AB; Bower JH; Hardy JA; Rocca WA
Mov Disord; 2002 Nov; 17(6):1305-11. PubMed ID: 12465073
[TBL] [Abstract][Full Text] [Related]
13. [Extrapyramidal side effects of neuroleptic and antidepressant treatment: assessment of potential risk factors through CYP2D6 genetic polymorphism].
Reggiani K; Vandel P; Haffen E; Sechter D; Bizouard P; Vandel S
Encephale; 2000; 26(1):62-7. PubMed ID: 10875063
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes.
Mas S; Gassó P; Lafuente A; Bioque M; Lobo A; Gonzàlez-Pinto A; Olmeda MS; Corripio I; Llerena A; Cabrera B; Saiz-Ruiz J; Bernardo M;
Pharmacogenomics J; 2016 Oct; 16(5):439-45. PubMed ID: 27272046
[TBL] [Abstract][Full Text] [Related]
15. Possible interaction between MAOA and DRD2 genes associated with antisocial alcoholism among Han Chinese men in Taiwan.
Wang TJ; Huang SY; Lin WW; Lo HY; Wu PL; Wang YS; Wu YS; Ko HC; Shih JC; Lu RB
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):108-14. PubMed ID: 17007976
[TBL] [Abstract][Full Text] [Related]
16. Serotonin transporter, tryptophan hydroxylase, and monoamine oxidase A gene polymorphisms in premenstrual dysphoric disorder.
Magnay JL; Ismail KM; Chapman G; Cioni L; Jones PW; O'Brien S
Am J Obstet Gynecol; 2006 Nov; 195(5):1254-9. PubMed ID: 17026953
[TBL] [Abstract][Full Text] [Related]
17. Increased hexosaminidase activity in antipsychotic-induced extrapyramidal side effects: possible association with higher occurrence in bipolar disorder patients.
Tunca Z; Resmi H; Ozkara HA; Ciliv G; Celtikci B; Alptekin K; Ozerdem A; Akdede BK; Baykara B; Birsoy B; Ergor G
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jul; 32(5):1214-20. PubMed ID: 18436361
[TBL] [Abstract][Full Text] [Related]
18. An interaction between the norepinephrine transporter and monoamine oxidase A polymorphisms, and novelty-seeking personality traits in Korean females.
Lee BC; Yang JW; Lee SH; Kim SH; Joe SH; Jung IK; Choi IG; Ham BJ
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):238-42. PubMed ID: 17920180
[TBL] [Abstract][Full Text] [Related]
19. Schizophrenia and functional polymorphisms in the MAOA and COMT genes: no evidence for association or epistasis.
Norton N; Kirov G; Zammit S; Jones G; Jones S; Owen R; Krawczak M; Williams NM; O'Donovan MC; Owen MJ
Am J Med Genet; 2002 Jul; 114(5):491-6. PubMed ID: 12116182
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms.
Hedenmalm K; Güzey C; Dahl ML; Yue QY; Spigset O
J Clin Psychopharmacol; 2006 Apr; 26(2):192-7. PubMed ID: 16633151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
